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Sequencing and reversion analysis of murine hepatitis virus (MHV) temperature-sensitive (ts) viruses has
identified putative ts mutations in the replicase nonstructural proteins (nsp’s) of these coronaviruses. In this
study, reverse transcriptase PCR sequencing of the RNA genome of an isolate of the MHV ts virus Alb ts6,
referred to as Alb/ts/nsp5/V148A, identified a putative ts mutation in nsp5 (T10651C, Val148Ala), the viral
3C-like proteinase (3CLpro). The introduction of the T10651C mutation into the infectious MHV clone resulted
in the recovery of a mutant virus, the nsp5/V148A virus, that demonstrated reduced growth and nsp5 protein-
ase activity identical to that of Alb/ts/nsp5/V148A at the nonpermissive temperature. Sequence analysis of 40°C
revertants of Alb/ts/nsp5/V148A identified primary reversion to Ala148Val in nsp5, as well as two independent
second-site mutations resulting in Ser133Asn and His134Tyr substitutions in nsp5. The introduction of the
Ser133Asn or His134Tyr substitution into the cloned nsp5/V148A mutant virus background resulted in the
recovery of viruses with increased growth fitness and the partial restoration of nsp5 activity at the nonper-
missive temperature. Modeling of the nsp5 structure of Alb/ts/nsp5/V148A predicted that the Val148Ala
mutation alters residue 148 interactions with residues of the substrate binding S1 subsite of the nsp5 active-site
cavity. This study identifies novel residues in nsp5 that may be important for regulating substrate specificity
and nsp5 proteinase activity.
Coronaviruses (CoVs) belong to a family of enveloped, pos-
itive-strand RNA viruses that cause important diseases in hu-
mans and animals. The identification of a novel human CoV as
the etiological agent of severe acute respiratory syndrome
(SARS) highlights the potential of this virus family to cause
severe and acute disease in the human population (13, 18, 36).
Additionally, the increasing identification of CoVs in bats and
other animals (37), combined with the threat of CoV transspe-
cies transmission, underscores the need to better understand
the replication strategies of these viruses in order to identify
improved targets for attenuation and interference with repli-
cation.
The CoV murine hepatitis virus (MHV) has been used as a
model system to investigate the functions of viral proteins in
replication and pathogenesis. The MHV genome is approxi-
mately 32 kb in size and contains seven genes, with the first
encoding the nonstructural proteins (nsp’s) and genes 2 to 7
encoding the structural and accessory proteins of the virus. The
life cycle of MHV occurs exclusively in the host cell cytoplasm.
Following the entry of MHV into a cell, the RNA genome is
translated by host cell ribosomes from open reading frame 1
(ORF1), which consists of approximately 22 kb and encodes
nsp1 to nsp16 (Fig. 1A). ORF1 is comprised of two ORFs
(ORF1a and ORF1ab) that are connected by a 1 ribosomal
frameshift element (7, 9, 29, 34). Translation of the ORF1a or
the ORF1ab fusion polyprotein (pp1a or pp1ab, respectively)
results in 495-kDa (pp1a) or 803-kDa (pp1ab) polyproteins
that are processed by three virus-encoded proteinases, includ-
ing two papainlike proteinase domains (PLP1 and PLP2) in
nsp3 and the cysteine proteinase nsp5 (3C-like proteinase
[3CLpro] or Mpro [stands for main proteinase], hereinafter
referred to as nsp5 or 3CLpro), to yield intermediate and
mature forms of nsp1 to nsp16 (4, 7, 16, 25, 33) (Fig. 1B).
The MHV and SARS-CoV nsp5 amino acid sequences share
50% sequence identity (Fig. 1C), and the alignment of group 1,
2, and 3 CoVs with MHV and SARS shows that they all
contain the catalytic-dyad residues (His41 and C145 for
MHV), as well as the conserved Tyr161-Met162-His163 motif,
which comprises the substrate binding S1 subsite of the pro-
teinase active-site cavity (Fig. 1C). MHV and SARS-CoV
nsp5s cleave the ORF1ab polyprotein at 11 conserved sites
following P2-Leu-Gln sequences. These processing events in-
clude the autoproteolytic liberation of nsp5 from the nascent
polyprotein (Fig. 1B) (31, 33). It has been demonstrated that
continuous expression and processing of the replicase polypro-
tein is required for ongoing and efficient RNA synthesis during
MHV replication (28, 38). Additionally, it has been shown that
mutation of the catalytic-dyad His41 or Cys145 residues of
MHV nsp5 abolishes the proteolytic activity of the protein
(32, 33).
Over the past 30 years, several panels of MHV temperature-
sensitive (ts) mutant viruses were established by chemical mu-
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tagenesis and were proposed to have ts mutations in the rep-
licase nsp’s based on viral complementation studies (41).
Recently, sequencing of the replicase genes of several of these
previously known ts viruses identified mutations predicted to
be responsible for the ts phenotypes (39), one of which has
experimentally been confirmed to occur in nsp10 using reverse
genetic introduction of the identified mutation into the infec-
tious MHV clone (17). In this study, we report a novel and
previously unknown mutation in the MHV nsp5 coding region
of ORF1a (T10651C, Val148Ala) that is responsible for the ts
phenotype of an isolate of Alb ts6, Alb/ts/nsp5/V148A. When
this single-nucleotide change was engineered into the infec-
tious MHV clone, the recovered recombinant nsp5/V148A
mutant virus displayed ts replication defects associated with
decreased nsp5 proteinase activity at the nonpermissive tem-
perature. We confirmed two independent second-site rever-
sion mutations in nsp5 that partially restored growth fitness
and nsp5 proteinase activity at the nonpermissive temperature.
Modeling of the nsp5 structures of MHV wild-type (WT), nsp5
ts, and nsp5 revertant viruses predicted that residue 148 of
nsp5 interacts with and may help stabilize the substrate binding
S1 subsite of the nsp5 active-site cavity.
MATERIALS AND METHODS
Viruses, cells, and antisera. Recombinant WT MHV strain A59 (GenBank
accession no. AY910861 [15, 40]) was used as the WT control for all experiments.
An isolate of Alb ts6 from 29 June 1989, labeled Al6 R.V. 6/89 (R.V. stands for
recovered virus), was kindly provided by Paul Masters (Wadsworth Center, New
York State Department of Health) (41). Delayed brain tumor cells selected for
high-level expression of the MHV receptor, carcinoembryonic antigen cell ad-
hesion molecule 1 (DBT-9) (12, 23, 44), and baby hamster kidney 21 cells
expressing the MHV receptor (BHK-MHVR cells) (11, 12, 44) were grown in
Dulbecco’s modified Eagle medium (DMEM) (Gibco) supplemented with 10%
heat-inactivated fetal calf serum (FCS) for all experiments. Medium for BHK-
MHVR cells was supplemented with G418 (0.8 mg/ml) to maintain selection for
cells expressing the MHV receptor. All polyclonal antisera used for biochemical
experiments have previously been described. These antisera include guinea pig
anti-nsp1 antiserum (GP3) (10) and rabbit anti-nsp8 antiserum (VU123) (8).
Sequence analysis of Alb/ts/nsp5/V148A. The Alb/ts/nsp5/V148A genome was
sequenced using a strategy previously described (40). The genome sequence was
compared to the WT strain from which Larry Sturman originally isolated the Alb
series of ts mutants (GenBank accession no. AY700211 [41]). Briefly, to obtain
total intracellular RNA for sequence analysis, cells in 25-cm2 flasks were infected
at 30°C using a multiplicity of infection (MOI) of 0.1 PFU/cell. When 10%
of the cells were involved in syncytia, total intracellular RNA was extracted using
TRIzol reagent (Invitrogen) according to the manufacturer’s protocol and used
as template for reverse transcriptase PCR (RT-PCR). Reverse transcription was
performed using SuperScript III RT (Invitrogen) and random hexamers at 55°C
for 60 min. The Alb/ts/nsp5/V148A cDNA was then PCR amplified using Easy-A
high-fidelity PCR cloning enzyme (Stratagene) or Elongase (Invitrogen) DNA
polymerase and oligonucleotides specific for the MHV genome (NCBI accession
no. 1NC001846). Sequencing primers were created every 600 bp, beginning with
the 5 end, from both the sense and antisense strands. These primers generated
overlapping sequences spanning the cDNA at least twice. Amplicons were gel
purified and directly analyzed by automated DNA sequencing. Sequences of
PCR and sequencing primers are available upon request.
Reversion analysis of Alb/ts/nsp5/V148A. Alb/ts/nsp5/V148A was grown over-
night at 40°C, and at 24 h postinfection (p.i.), virus was collected from the culture
supernatant. Total intracellular RNA for sequence analysis was obtained from
cells in 25-cm2 flasks that were infected at an MOI of 0.1 PFU/cell at 40°C.
When 10% of the cells were involved in syncytia, total intracellular RNA was
extracted using TRIzol reagent (Invitrogen), as described above, and used as a
template for RT-PCR. Reverse transcription was performed using SuperScript
III RT (Invitrogen) and random hexamers at 55°C for 60 min. The genome was
sequenced across the four genomic regions containing the nonsynonymous mu-
tations identified in Alb/ts/nsp5/V148A. The nsp3 coding region was amplified
using PCR with primers corresponding to nucleotides (nt) 4232 to 4248 (sense)
and nt 5913 to 5929 (antisense). The nsp5 coding region was amplified using PCR
with primers corresponding to nt 10157 to 10176 (sense) and nt 11782 to 11798
(antisense). The nsp7 coding region was amplified using PCR with primers
corresponding to nt 11330 to 11347 (sense) and nt 13345 to 13361 (antisense).
The nucleocapsid (N) coding region was amplified using PCR with primers
corresponding to nt 28729 to 28746 (sense) and nt 30129 to 30145 (antisense).
FIG. 1. MHV proteolytic processing of the ORF1ab polyprotein
and comparison of MHV and SARS-CoV nsp5 sequences. (A) Sche-
matic of the MHV genome. The approximately 32-kb MHV genome is
shown as a line, and the locations of gene 1 (22 kb) and genes 2 to
7 (9.5 kb) are indicated. Gene 1 is composed of two ORFs (labeled
arrows) connected by a 1 ribosomal frameshift element. (B) Sche-
matic of PLP1, PLP2, and nsp5 processing of pp1a and pp1ab. Trans-
lation of ORF1a yields a pp1a of nsp1 to nsp10 or nsp11, shown on top
as connected boxes with each nsp numbered. Viral proteinases (PLP1,
PLP2, and nsp5) are shown as gray boxes. Bent black arrows show
cleavage events mediated by the indicated proteinase. The translation
of ORF1ab yields a theoretical nsp1-to-nsp16 pp1ab, shown on the
bottom as connected boxes with viral proteinases shown in gray. Down-
stream nsp5 cleavage events are indicated by bent black arrows.
(C) Sequence comparison of MHV and SARS-CoV nsp5 amino acid
sequences. The MHV nsp5 sequence is shown on the top and the
SARS-CoV (SCV) sequence is shown on the bottom. Residues con-
served between MHV and SARS-CoV have an asterisk beneath them.
Catalytic His41 and Cys145 and the conserved substrate binding S1
subsite residues Tyr161, Met162, and His163 are highlighted in gray.
Arrows denote MHV Ser133, His134, and Val148.
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Mutagenesis of MHV cDNA C fragment plasmids. The entire MHV-A59
genome was cloned as seven cDNA fragments, A through G, each in a separate
plasmid (44). The C fragment plasmid (pCR-XL-pSMART C), designed for the
recovery of WT virus VUSS3 (40), was used as a template for site-directed-PCR-
based mutagenesis to introduce the nsp5/Val148Ala substitution into the MHV
genome. Overlapping sense and antisense primers for nsp5/V148A (Table 1)
were used to generate mutant plasmids. To introduce the nsp5/Ser133Asn and
nsp5/His134Tyr substitutions into the MHV genome, the C fragment plasmid
was used as a template. To engineer nsp5/Ser133Asn/Val148Ala and nsp5/
His134Tyr/Val148Ala substitutions into the MHV genome, the nsp5/V148A
mutant plasmid was used as a template for PCR-based mutagenesis. Overlapping
sense and antisense primers for nsp5/Ser133Asn and nsp5/His134Tyr (Table 1)
were used to generate mutant plasmids. The sequences of all mutant fragments
were verified.
Generation of MHV nsp5 mutant viruses. Viruses containing the engineered
mutations within nsp5 were produced by using the infectious cDNA assembly
strategy for MHV-A59 described by Yount et al. (44) and modified by Denison
et al. (15). Briefly, plasmids containing the seven cDNA cassettes of the MHV
genome were digested using the appropriate restriction enzymes. Gel-purified
restriction fragments were ligated together in a total reaction volume of 50 l
overnight at 16°C. Following the chloroform extraction and isopropanol precip-
itation of ligated DNA, full-length transcripts of MHV cDNA were generated in
vitro using the mMessage mMachine T7 transcription kit (Ambion) and by
following the manufacturer’s protocol with modifications. Fifty-microliter reac-
tion mixtures were supplemented with 7.5 l of 30 mM GTP, and transcription
was performed at 40.5°C for 30 min, 37°C for 60 min, 40.5°C for 30 min, 37°C for
30 min, and 40.5°C for 30 min. In parallel, transcripts encoding the MHV N
protein were generated from N cDNA. To prepare for electroporation, BHK-
MHVR cells were grown to subconfluence, trypsinized, and then washed twice
with phosphate-buffered saline (PBS) and resuspended in PBS at a concentration
of 1  107 cells/ml. From the resuspended cell solution, a 600-l aliquot of cells
was added to N and MHV transcripts in a 4-mm-gap electroporation cuvette.
Three pulses of 850 V at 25 F were delivered to the cuvette with a Bio-Rad
Gene Pulser II electroporator. Electroporated cells were then laid over a layer of
1  106 uninfected DBT-9 cells in a 75-cm2 flask and incubated at 30°C and 40°C.
Virus viability was determined by its cytopathic effect (syncytium formation) in
the electroporated cell culture. Progeny virus in the culture medium of electro-
porated cells (passage 0 [P0]) was passed onto uninfected DBT-9 cells (P1 cells),
and the virus released in the culture medium was designated P1 stock. For each
recovered virus, RNA harvested from P1 cells was RT-PCR amplified and
sequenced across the nsp5 coding region, using PCR with primers corresponding
to nt 10157 to 10176 (sense) and nt 11782 to 11798 (antisense) to verify the
sequence.
Viral growth analysis. WT and nsp5 mutant viruses were analyzed for repli-
cation by using growth assays as previously described (15). Briefly, DBT-9 cells
in 60-mm dishes were infected with WT or nsp5 mutant viruses in growth
medium at an MOI of 0.1 PFU/cell. Following a 30-min adsorption at room
temperature, the inoculum was removed, and cells were washed three times with
PBS and supplied with prewarmed 10% FCS-DMEM. Cells were then incubated
at either 30°C or 40°C. Samples of media were collected from 1 to 36 h p.i., and
virus titers were determined by plaque assay at 30°C as described previously (28).
To enhance the visualization of plaques, cells under an agar growth medium
overlay were fixed with 4% formaldehyde at room temperature. The overlay was
then discarded, and the fixed cell monolayer was air dried before plaques were
counted.
Immunoprecipitation of radiolabeled viral proteins. For constant-tempera-
ture experiments, confluent monolayers of DBT-9 cells in 60-mm cell culture
dishes were either infected with virus at an MOI of 5 PFU/cell or mock infected
with 10% FCS-DMEM at either 30°C or 40°C. At 5.5 h p.i., the medium was
replaced with 10% FCS-DMEM lacking methionine and cysteine and supple-
mented with 5 g/ml actinomycin D. Cells were incubated from 6 to 8 h p.i. with
100 Ci/ml of [35S]methionine-cysteine (Translabel; ICN). At 8 h p.i., cells were
lysed in 500 l of lysis buffer (150 mM sodium chloride [NaCl], 1% NP-40, 0.5%
sodium deoxycholate, 50 mM Tris [pH 8.0]). Lysates were then centrifuged at
3,500  g for 5 min to remove cell nuclei, and the supernatant was retained as the
post-nuclear-removal lysate. For temperature shift experiments, confluent mono-
layers of DBT-9 cells in 60-mm dishes were either infected at an MOI of 5
PFU/cell or mock infected with 10% FCS-DMEM at 30°C. At 20 h p.i., the cells
were shifted to 40°C. At 23.5 h p.i., the medium was replaced with 10% FCS-
DMEM lacking methionine and cysteine and supplemented with 5 g/ml acti-
nomycin D. Cells were incubated from 24 to 26 h p.i. with 100 Ci/ml of
[35S]methionine-cysteine (Translabel; ICN). At 26 h p.i., cells were lysed and
post-nuclear-removal lysates were generated, as described above. Immunopre-
cipitations were performed in a final volume of 1 ml, using protein A-Sepharose
beads (Sigma), 50 l of radiolabeled lysate (derived from approximately 1  106
cells), and a 1:500 dilution of polyclonal antiserum in lysis buffer. Following an
overnight incubation at 4°C, protein-bead conjugates were pelleted by centrifu-
gation at 12,000  g for 1 min and washed in low-salt lysis buffer (lysis buffer with
150 mM NaCl) followed by high-salt lysis buffer (lysis buffer with 1 M NaCl) and
a final low-salt wash. After being rinsed, proteins were eluted by the addition of
2 lithium dodecyl sulfate buffer with 1 dichlorodiphenyltrichloroethane (Nu-
PAGE; Invitrogen) to the beads, which were heated at 70°C for 10 min prior to
electrophoresis. Proteins were resolved by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) in 4 to 12% polyacrylamide gradient
Bis-Tris gels (NuPAGE; Invitrogen) and analyzed by fluorography. The 14C-
labeled high-molecular-weight standard (New England Biolabs) and full-range
rainbow marker (RPN 800; Invitrogen) were used as molecular weight standards.
Modeling of MHV nsp5 structures. The crystal structure coordinates of SARS
3CLpro (Protein Data Bank [PDB] code 2H2Z, chain A) (42) were used as a
template to generate a homology model of MHV nsp5 using the online program
3D-Jigsaw in the automatic mode (5, 6, 14). The root mean square distance
(RMSD) between the template and the model was determined to be 0.708
angstroms, using the molecular-modeling tool Chimera (35). The MHV nsp5
model was then used as a template for introducing the ts genotype of the
nsp5/V148A virus as well as the genotypes of both of the second-site revertant
mutants, the nsp5/S133N/V148A and nsp5/H134Y/V148A viruses, using the Ro-
settaDesign Web server (http://rosettadesign.med.unc.edu/) (30). In each case,
the MHV nsp5 model was analyzed using the molecular-modeling tool MacPyMOL
(DeLano Scientific) to determine which amino acids were proximal to the amino
acid(s) being targeted for replacement. Briefly, each amino acid to be altered was
highlighted, and all other amino acids within an interaction distance of 5 ang-
stroms were identified. Using the RosettaDesign website, the amino acid re-
placements were incorporated, and all amino acids within the 5-angstrom inter-
action distance were relaxed to allow the program to repack the side chains to an
optimal energetic state. This process was repeated with each mutation and each
series of mutations. Ten models were generated for each set of mutations, and
the best model, based on the lowest energy score, was selected and further
evaluated using MacPyMOL. In addition, an online version of the program
WHAT_IF (24) was used to identify the optimal hydrogen bonding networks for
the MHV nsp5 model and the nsp5/V148A, nsp5/S133N/V148A, and nsp5/
H134Y/V148A models.
RESULTS
Genome sequence analysis of Alb/ts/nsp5/V148A. Previous
sequence analysis of the MHV ts virus Alb ts6 identified the
mutation A9494C in the nsp4 coding sequence as a candidate
ts mutation (39). Because only the replicase gene was se-
quenced in that study, we sought to determine if additional
mutations were present in genes 2 to 7 that might contribute to
TABLE 1. Oligodeoxynucleotides used for the mutagenesis of
MHV cDNA C fragment plasmids
Primer target Polarity Sequencea
nsp5/V148A Sense 5-AGT TAA AAC ATA TCC TGC
AGA ACC GCA GGA TCC-3
Antisense 5-GGA TCC TGC GGT TCT GCA
GGA TAT GTT TTA ACT-3
nsp5/S133N Sense 5-GTT ACG CTT CGT AGT AAC
CAT ACC ATA AAG GGC-3
Antisense 5-GCC CTT TAT GGT ATG GTT
ACT ACG AAG CGT AAC-3
nsp5/H134Y Sense 5-ACG CTT CGT AGT AGC TAT
ACC ATA AAG GGC TCC-3
Antisense 5-GGA GCC CTT TAT GGT ATA
GCT ACT ACG AAG CGT-3
a Underlined nucleotides represent nucleotides altered from the WT se-
quence.
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the ts phenotype of Alb ts6 prior to reverse genetic testing of
the nsp4 mutation. We obtained an original isolate of Alb ts6,
Alb/ts/nsp5/V148A. DBT-9 cells were infected with Alb/ts/
nsp5/V148A at 30°C, RNA was harvested, and the complete
viral genome was obtained by RT-PCR sequence analysis. The
results of genome sequencing identified numerous synonymous
mutations (noncoding or untranslated-region mutations) and
four nonsynonymous mutations (Fig. 2). Three of the nonsyn-
onymous mutations were located in regions of ORF1a encod-
ing nsp3 (C5265A, Leu854Met), nsp5 (T10651C, Val148Ala),
and nsp7 (C12225T, Arg83Cys). The fourth mutation was lo-
cated in the N gene (G29690C, Glu8Gln). We did not detect an
A9494C mutation (Asn258Thr) in the nsp4 coding sequence.
These results indicate that the Alb ts6 isolate that we analyzed,
Alb/ts/nsp5/V148A, is a virus different than the Alb ts6 virus
described by Sawicki et al. (39).
Identification of a novel ts mutation in MHV nsp5. To iden-
tify the mutation(s) responsible for the ts phenotype of Alb/ts/
nsp5/V148A, DBT-9 cells were infected with Alb/ts/nsp5/
V148A at the nonpermissive temperature (40°C), and the virus
was harvested at 24 h p.i. A plaque assay was performed at
40°C on the recovered virus, and 10 virus plaques were picked.
Plaques were then expanded at 40°C in T25 flasks, and total
cellular RNA was obtained. Each isolated virus was RT-PCR
sequenced across the regions of the genome that contained
nonsynonymous mutations in Alb/ts/nsp5/V148A. The muta-
tions identified in nsp3, -7, and -14 and N were maintained in
all 10 plaque isolates. Sequencing across nsp5 of the plaque
isolates revealed either reversion to the WT sequence
(C10651T, Ala148Val) or the continued presence of the
T10651C mutation and an additional mutation in nsp5 at ei-
ther G10606A (Ser133Asn) or C10608 (His134Tyr) (Table 2).
Together, these sequencing results identified the single
T10651C mutation in nsp5 as a candidate ts mutation and two
additional independent mutations in nsp5 as candidate second-
site revertant mutations.
To test the phenotypes of the candidate MHV nsp5 ts and
second-site revertant mutations, we used reverse genetics to
engineer each mutation into the infectious MHV clone, either
alone or in combination. Each virus was named on the basis of
its nsp, with “nsp5” followed by a forward slash and the single-
letter amino acid substitution(s), as follows: nsp5/V148A, nsp5/
S133N, nsp5/H134Y, nsp5/S133N/V148A, and nsp5/H134Y/
V148A. The mutant viral genomes were electroporated into
cells, and cells were incubated at 30°C and monitored for the
formation of virus-induced syncytia. All five mutant viruses
(the nsp5/V148A, nsp5/S133N, nsp5/H134Y, nsp5/S133N/V148A,
and nsp5/H134Y/V148A viruses) were recovered at 30°C, dem-
onstrating that the mutations introduced into the MHV genome
were not lethal for virus replication. Viruses harvested from elec-
troporated cells (P0) were expanded at 30°C in T150 flasks to
generate the P1 stocks that were used in all subsequent experi-
ments. Each recovered virus was sequenced to verify that the
introduced mutations were maintained in the genome and that no
additional mutations were present in the nsp5 coding region.
To determine if the nsp5 mutant viruses were ts, plaque
assays were performed on DBT-9 cells using WT and nsp5
mutant viruses at permissive (30°C) and nonpermissive (40°C)
temperatures. Following these plaque assays, the efficiency of
plating (EOP) values were calculated (Table 2). The EOP for
WT virus was 3.3, confirming that there was no impairment of
growth at 40°C. In contrast, the recombinant Alb/ts/nsp5/
FIG. 2. Nonsynonymous mutations identified in Alb/ts/nsp5/
V148A. (A) The first column shows the MHV protein containing the
mutation. The second column shows the genome nucleotide number of
the mutation. The third column shows the codon and corresponding
amino acid (aa) change in the protein. The last column indicates the
reversion of the nonsynonymous change following growth of the virus
at 40°C. The amino acid number refers to the amino acid number
within the indicated MHV protein. (B) The schematic shows MHV
ORF1ab, with individual nsp’s labeled as rectangular boxes 1 to 16.
PLP1 and PLP2 in nsp3 are shown as stippled gray lines. Labeled
arrows point to regions in the proteins where nonsynonymous changes
were identified. The change in the N protein is not shown.
TABLE 2. Determination of nsp5 mutant virus ts phenotype
Virus strain
Amino acid at position: Titer at:a
EOPb
133 134 148 30°C 40°C
WT Ser His Val 9.0  107 3.0  108 3.3
Alb/ts/nsp5/V148A Ser His Ala 2.8  108 8.5  104 3  104
nsp5/V148A virus Ser His Ala 1.0  108 2.0  103 2  105
nsp5/S133N virus Asn His Val 1.8  106 5.5  106 3.1
nsp5/H134Y virus Ser Tyr Val 6.5  105 2.0  106 3.1
nsp5/S133N/V148A virus Asn His Ala 2.8  107 3.8  107 1.4
nsp5/H134Y/V148A virus Ser Tyr Ala 4.0  106 4.3  106 1.1
a Values for titers indicated are in PFU/ml.
b EOPs are titers at 40°C divided by titers at 30°C.
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V148A virus had an EOP of 3  104, demonstrating a ts
defect similar to that originally reported for Alb ts6 (41). The
engineered nsp5/V148A virus had an EOP of 2  105, indi-
cating that the single T10651C mutation was sufficient to con-
fer the ts phenotype on the virus. The nsp5/S133N and nsp5/
H134Y mutant viruses had EOPs of 3.1, very close to the EOP
calculated for the WT virus. These results demonstrate that the
Ser133Asn and His134Tyr mutations in nsp5 are not detrimen-
tal to virus growth and do not confer a ts phenotype on the
virus. The nsp5/S133N/V148A and nsp5/H134Y/V148A mu-
tant viruses had EOPs of 1.4 and 1.1, respectively, showing that
the Ser133Asn and His134Tyr mutations were each capable of
compensating for the ts defect caused by Val148Ala in this
assay. These results provide experimental confirmation that
the T10651C mutation in nsp5 is responsible for the ts pheno-
type of Alb/ts/nsp5/V148A. Additionally, the results indicate
that the presence of either Ser133Asn or His134Tyr in the
nsp5/V148A virus is sufficient to compensate for the ts defect at
the nonpermissive temperature. Because no significant virus
growth defects were observed for the nsp5/S133N or nsp5/
H134Y virus, all subsequent studies were performed with
WT, Alb/ts/nsp5/V148A, nsp5/V148A, nsp5/S133N/V148A,
and nsp5/H134Y/V148A viruses.
Growth analysis of nsp5 mutant viruses in culture. Al-
though the Ser133Asn and His134Tyr substitutions were indi-
vidually capable of compensating for the Val148Ala ts defect as
measured by EOP, the nsp5/S133N/V148A and nsp5/H134Y/
V148A mutant viruses still had EOPs two- to threefold less
than those of WT MHV and the nsp5/S133N and nsp5/H134Y
mutant viruses. These results suggest that neither second-site
mutation completely compensated for the Val148Ala ts defect.
To further analyze the replication characteristics of the nsp5
mutant viruses and identify subtle replication defects, DBT-9
cells were infected with the WT, Alb/ts/nsp5/V148A, nsp5/
V148A, nsp5/S133N/V148A, or nsp5/H134Y/V148A virus at
an MOI of 0.01 PFU per cell at 30°C and 40°C. Samples of
infected cell culture media were obtained at various times from
1 to 36 h p.i., and virus titers in each sample were determined
by plaque assay at 30°C (Fig. 3).
Growth curves of viruses examined at 40°C mirrored the ts
defect observed during the plaque reduction assays (Fig. 3A).
The WT virus reached peak titers at 8 h p.i., at which time the
cell monolayer was largely destroyed, and virus titers gradually
declined. Growth of the Alb/ts/nsp5/V148A and nsp5/V148A ts
mutant viruses was below the limits of detection of the assay
until after 8 h p.i., consistent with a complete ts block in
replication. After 8 h p.i., growth became exponential and
reached titers of approximately 107 PFU/ml by 36 h p.i., sug-
gesting the emergence of revertant viruses. Virus samples ob-
tained at 24 h p.i. for Alb/ts/nsp5/V148A and the nsp5/V148A
virus were sequenced across the nsp5 coding region to examine
this possibility. In both cases, primary-site revertants (C10651T
virus) were identified. These results confirm the ts and rever-
sion phenotypes of Alb/ts/nsp5/V148A and the nsp5/V148A
virus. The Ser133Asn and the His134Tyr mutations in the
nsp5/V148A virus backbone restored the growth fitness of the
ts virus at the nonpermissive temperature, but incompletely
and to different extents (Fig. 3A). The nsp5/H134Y/V148A
mutant virus grew with growth kinetics similar to those of the
WT virus but showed a lag in growth beginning at 4 h p.i. and
did not reach peak titer until 12 h p.i., at which point the cell
monolayer was largely destroyed. The nsp5/S133N/V148A mu-
tant virus reached titers 10-fold greater than those of Alb/ts/
nsp5/V148A or the nsp5/V148A virus at 4 and 8 h p.i., at least
100-fold less than those of the nsp5/H134Y/V148A virus, and
approximately 1,000-fold less than those of the WT virus at
these same time points. Interestingly, there was exponential
growth of the nsp5/S133N/V148A virus beginning between 8
and 16 h p.i., at which point the cell monolayer was destroyed.
These results show that the Ser133Asn and His134Tyr muta-
tions are each capable of compensating for the Val148Ala ts
defect at the nonpermissive temperature. However, the sec-
ond-site revertant viruses remain less fit than the WT virus,
arguing that the Ser133Asn and His134Tyr substitutions do not
completely repair the replication defect of the nsp5/V148A
virus. In addition, the late change to exponential growth for
both the nsp5/S133N/V148A and nsp5/H134Y/V148A viruses
suggests that there remains significant pressure for additional
compensating mutations in locations yet to be determined.
FIG. 3. Growth analysis of WT, ts, and revertant viruses. (A) Virus
growth at 40°C. DBT-9 cells were infected with the indicated viruses at
an MOI of 0.01 PFU/cell. Samples of virus supernatants were obtained
at 1, 4, 8, 12, 16, 24, and 36 h p.i., and virus titers were determined by
plaque assay at 30°C on DBT-9 cells. (B) Virus growth at 30°C. DBT-9
cells were infected with the indicated viruses at an MOI of 0.01 PFU/
cell. Samples of virus supernatants were obtained at 1, 4, 8, 12, 16, 24,
and 36 h p.i., and virus titers were determined by plaque assay at
30°C on DBT-9 cells. (V148A, nsp5/V148A virus; S133N/V148A,
nsp5/S133N/V148A virus; H134Y/V148A, nsp5/H134Y/V148A vi-
rus).
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Growth curves of all viruses tested at 30°C had similar pat-
terns of multiple-cycle replication following infection at a low
MOI (Fig. 3B). This growth pattern manifested as exponential
growth until about 4 to 8 h p.i., followed by a plateau in growth
until 12 h p.i. and subsequent resumption of exponential
growth. Though the growth curves had similar patterns, the
times and extents of peak titer varied for each of these viruses.
The WT virus grew to the highest titers of all viruses tested,
achieving titers greater than 108 PFU/ml by 24 h p.i. Alb/ts/
nsp5/V148A, the nsp5/V148A virus, and the nsp5/H134Y/
V148A virus all grew with similar patterns of growth, showing
growth reduced approximately 10-fold in comparison to that of
the WT virus at up to 24 h p.i. but increasing to approximately
108 PFU/ml at 36 h p.i. Over the course of the experiment, the
nsp5/S133N/V148A mutant virus grew with titers reduced 10-
to 100-fold in comparison to those of the WT virus. These
results indicate that the V148A substitution in nsp5 has subtle
replication defects, even at the permissive temperature. Fur-
ther, the compensating second-site changes S133N and H134Y
that restore growth fitness to the nsp5/V148A virus at the
nonpermissive temperature render the revertant viruses less fit
than either the WT or the nsp5/V148A virus at the permissive
temperature. Whether the ts and constitutive defects result
from the same mechanism or different mechanisms remains to
be determined.
Replicase protein expression and processing of nsp5 mutant
viruses. MHV nsp1 to nsp3 of the replicase polyprotein are
processed by PLP1 and PLP2 in nsp3, and nsp4 to nsp16 are
processed by nsp5 (3CLpro). To test the activities of nsp3
(PLP1 and PLP2) and nsp5 proteinases, DBT-9 cells were
infected with the WT or nsp5 mutant virus at 30°C and radio-
labeled from 6 to 9 h p.i. with [35S]Met-Cys, and cell lysates
were immunoprecipitated with antibodies specific for nsp8, a
viral replicase protein that is cleaved from pp1a by nsp5. At
30°C, anti-nsp8 immunoprecipitated the 22-kDa nsp8 protein
from lysates of cells infected with the Alb/ts/nsp5/V148, nsp5/
V148A, nsp5/S133N/V148A, and nsp5/H134Y/V148A viruses
but not from mock-infected cell lysates (Fig. 4A), demonstrat-
ing that nsp5 processing activity is intact at the permissive
temperature for the mutant viruses. The 22-kDa nsp8 band
appeared very faint in WT-infected cell lysates. This result was
consistent across four individual experiments. Additionally, the
150-kDa precursor protein, nsp4 to nsp10 (22, 26, 27), was
detected in all virus-infected cell lysates, confirming the trans-
lation of pp1a. Interestingly, a distinct band of unknown origin
of approximately 59 kDa, seen only in the 30°C immunopre-
cipitations, was detected in all infected cell lysates. To test the
activity of the nsp3 proteinase PLP1, antiserum specific for
nsp1 was used to immunoprecipitate the 28-kDa nsp1 protein
from cell lysates. Because nsp1 is cleaved from the polyprotein
by PLP1, the presence of a cleavage product in the ts viruses at
the nonpermissive temperature would demonstrate that the
viruses were replicating and that PLP1 was active. The results
showed that anti-nsp1 immunoprecipitated nsp1 from the ly-
sates of cells infected with the WT, Alb/ts/nsp5/V148A, nsp5/
V148A, nsp5/S133N/V148A, and nsp5/H134Y/V148A viruses
but not from mock-infected cell lysates (Fig. 4C), confirming
the intact function of PLP1 in all viruses tested at 30°C. The
presence of an nsp1 doublet was observed in several of the
viruses, suggesting either alternative cleavage products of nsp1
or the presence of posttranslational modifications.
It was not possible to determine the processing of the nsp5
ts viruses in cells infected at 40°C because viral protein prod-
ucts could not be detected. To access processing at the non-
permissive temperature, cells were infected at 30°C and then
shifted to 40°C at 24 h p.i. Viral proteins were metabolically
radiolabeled from 26 to 28 h p.i. with [35S]Met-Cys, and at 28 h
p.i., cell lysates were harvested and immunoprecipitated with
FIG. 4. Activity of PLP1 and nsp5 (3CLpro) in processing replicase
nsp1 and nsp8. Cytoplasmic lysates were generated from radiolabeled
DBT-9 cells that were either mock infected or infected with the WT,
Alb/ts/nsp5/V148A (Alb/ts/nsp5), nsp5/V148A (V148A), nsp5/S133N/
V148A (S133N), or nsp5/H134Y/V148A (H134Y) virus at 30°C with
labeling from 26 to 28 h p.i. (A and C) or at 30°C for 24 h followed by
a shift to 40°C from 24 to 28 h p.i. with labeling from 26 to 28 h p.i. (B
and D). Labeled proteins were immunoprecipitated with antiserum
specific for nsp8 (A and B) or nsp1 (C and D), as indicated below each
gel. Proteins were resolved by SDS-PAGE in 4 to 12% polyacrylamide
gradient gels and visualized using fluorography. The numbers on the
left side of the gel represent molecular mass markers (in kDa), and
arrows to the right of gels point to the indicated proteins. , anti.
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antibodies specific for nsp8 or nsp1. When lysates were immu-
noprecipitated with anti-nsp8, mature 22-kDa nsp8 was de-
tected in WT-infected cell lysates following the shift to 40°C
(Fig. 4B). Additionally, a 150-kDa band consistent with the
known nsp4-to-nsp10 precursor was detected in the WT-in-
fected cell lysates but not in mock-infected cell lysates. In
contrast, immunoprecipitation with anti-nsp8 of lysates from
cells infected with the Alb/ts/nsp5/V148A, nsp5/V148A, nsp5/
S133N/V148A, or nsp5/H134Y/V148A virus detected various
nsp4 to nsp10 and nsp8 band intensities following the temper-
ature shift to 40°C. Minimal nsp4 to nsp10 and nsp8 were
detected from cell lysates infected with Alb/ts/nsp5/V148A or
the nsp5/V148A virus compared to the WT levels of nsp4 to
nsp10 and nsp8. Cell lysates infected with the nsp5/S133N/
V148A or nsp5/H134Y/V148A virus showed nsp4 to nsp10 and
nsp8 at intensities less than those of WT-infected cell lysates
but greater than those of Alb/ts/nsp5/V148A- or nsp5/V148A
virus-infected cell lysates. As seen at 30°C, a band of approx-
imately 59 kDa was also detected in each virus-infected cell
lysate but not in the mock-infected cell lysate (Fig. 4B). It is
unknown whether this band represents a cellular or viral pro-
tein. Immunoprecipitation using anti-nsp1 detected the mature
28-kDa nsp1 protein in lysates of cells infected with the WT,
Alb/ts/nsp5/V148A, nsp5/V148A, nsp5/S133N/V148A, and
nsp5/H134Y/V148A viruses, and nsp1 was not detected in
mock-infected cell lysates (Fig. 4D). The detection of nsp1 in
all virus-infected lysates demonstrates that at the nonpermis-
sive temperature, nsp’s are capable of being translated from
ORF1a and that the PLP1 function of nsp3 remains intact in
each of the nsp5 mutant viruses following the shift to 40°C.
Modeling of MHV nsp5, nsp5/V148A, nsp5/V148A/S133N,
and nsp5/V148A/H134Y. To define the locations of the nsp5
mutations identified in this study in the MHV nsp5 protein
structure, homology models of nsp5 were generated for WT
MHV, using the program 3D-Jigsaw (5, 6) (Fig. 5). The mu-
tations from nsp5/V148A, nsp5/S133N/V148A, and nsp5/
H134Y/V148A were added to this model by using the online
program RosettaDesign (Fig. 5). The backbone of the SARS-
CoV nsp5 structure (PDB code 2H2Z) (42) was then com-
pared to the structure in the homology model of MHV nsp5 by
using the MatchMaker tool under the structure comparison
section of Chimera, resulting in an RMSD of 0.743 Å. This low
RMSD value indicates that the structural identity between
MHV nsp5 and SARS-CoV nsp5 is high. The homology mod-
els of WT MHV nsp5, nsp5/V148A, nsp5/S133N/V148A, and
nsp5/H134Y/V148A were then analyzed and compared.
Like other CoV 3C-like proteinases, MHV nsp5 is predicted
to contain three domains, I to III (Fig. 5A). His41 and Cys145,
which make up the catalytic dyad of the proteinase, are located
in domains I and II, respectively. The active-site cavity, where
substrates are bound and the catalytic dyad mediates cleavage,
is formed by the interaction of domain I and domain II. The
conserved Tyr161, Met162, and His163 residues are found in
domain II in the active-site cavity and comprise the substrate
binding S1 subsite (Fig. 5B) (1). The nsp5/Val148 residue is
conserved between MHV and SARS-CoV and, based on the
MHV nsp5 homology model, is packed 3.91 Å from Met162
(Fig. 5C). This close proximity of Val148 to Met162 predicts
that hydrophobic interactions occur between the side chains of
the two amino acids. Modeling of the Ala148 mutation en-
coded by Alb/ts/nsp5/V148A and the nsp5/V148A virus does
not predict major disruptions in protein structure or organiza-
tion (Fig. 5D). Rather, Val148Ala is predicted to alter or limit
the hydrophobic interactions of residue 148 with Met162, re-
sulting in additional rotameric positions of Met162. Overall,
the model suggests that Val148 stabilizes the position of
Met162 in the S1 subsite of the active-site cavity.
The Ser133 and His134 residues are not predicted to be
found within or adjacent to the active-site cavity of nsp5 but
rather are predicted to be located in domain II on the opposing
side of the Tyr161-Met162-His163 motif from Val148 (Fig. 5B,
E, and F). Superimposition of the Ser133Asn and His134Tyr
substitutions onto the nsp5/V148A model predicts that Ser133
Asn and His134Tyr do not interact directly or indirectly with
the catalytic-dyad His41/Cys145 residues, the substrate binding
Tyr161-Met162-His163 residues, or residue Val148Ala. In
addition, there was no predicted propagation of structural
changes into the active-site cavity of the second-site revertant
viruses. Modeling of the His134Tyr mutation in nsp5/V148A
predicts only subtle alteration at residues Leu130, Ala131,
Ser132, His172, and Tyr182 (Fig. 5F). Interestingly, His172 has
been identified as a crucial residue required for the stabiliza-
tion of the interaction between the S1 subsite binding residue
His163 and the Gln residue in position 1 of the substrate (43).
In contrast, modeling of the Ser133Asn mutation predicted no
interactions or changes proximal to the active-site cavity (Fig.
5E). Instead, modeling predicted side chain modifications of
Ala131, Val195, Gly196, and Ala197, which are directed away
from the active-site cavity. Virus replication and protein pro-
cessing of the nsp5/S133N/V148A virus were more impaired
than those of the nsp5/H134Y/V148A virus, suggesting that
modifications induced by Ser133Asn compensate the nsp5/
Val148Ala defect less efficiently than His134Tyr. The impact of
these mutations on substrate selection or substrate binding
remains to be determined. However, the direct juxtaposition of
the residues selected for changes (Ser133 and His134 in MHV)
argues for conserved roles in the structure and function of
nsp5.
DISCUSSION
In this study, we identified a novel mutation (T10651C) that
results in a Val148Ala substitution in nsp5, the 3C-like pro-
teinase of MHV, that is responsible for the ts phenotype of
Alb/ts/nsp5/V148A, an original isolate of the MHV ts Alb ts6
mutant virus. Additionally, we identified two second-site re-
version mutations in nsp5 that partially compensate for the
replication and protein-processing defects that manifest at the
nonpermissive temperature. A recent published report on Alb
ts6 identified a mutation in nsp4 (A9494C, Asn258Thr) as the
Alb ts6 ts mutation (39). Interestingly, there was no overlap
between the nsp4 sequence results reported by Sawicki et al.
(39) for Alb ts6 and the results of the complete genome se-
quencing of Alb/ts/nsp5/V148A reported in this paper. We
therefore conclude that the previously reported Alb ts6 virus is
distinct from Alb/ts/nsp5/V148A characterized in this study.
The sequencing and reverse genetic studies presented in this
paper argue that the complete genome sequencing and reca-
pitulation of ts mutations by use of reverse genetic strategies
will be critical for future studies of ts mutant viruses.
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FIG. 5. Structural models of MHV nsp5s from WT, Alb/ts/nsp5/V148A, nsp5/S133N/V148A, and nsp5/H134Y/V148A viruses. A homology
model of the MHV nsp5 protein was generated with the program 3D-Jigsaw using the coordinates of the X-ray crystal structure of SARS-CoV nsp5
(PDB accession no. 2H2Z) as a template. RosettaDesign was used to model the remaining mutations. (A) The MHV nsp5 model contains three
domains shown as follows: domain I, red; domain II, blue; and domain III, gray. The substrate binding region is orange, and the catalytic dyad is
green. Val148, Ser133, and His134 are shown in yellow. (B) Expanded view of the putative active-site cavity of this structural model shows that
the catalytic dyad consists of His41 and Cys145, which are green. Critical substrate binding residues Tyr161, Met162, and His163 are orange. ts
residues, Val148, and revertant sites Ser133 and His134 are yellow. (C to F) ts and second-site mutations in MHV nsp5. All residues are colored
as for panel B, with nsp5 orientation shifted slightly to show interactions and changes associated with ts mutation and second-site revertants.
Domain I and domain II colors are faded to emphasize areas of interest. (C) Substrate binding pocket of WT MHV nsp5. Predicted electron
density maps, hydrophobic interactions, and side chain positions of Val148 (yellow) and Met162 (orange) proteins are indicated. (D) Substrate
binding pocket of nsp5/V148A. Predicted electron density maps, hydrophobic interactions, and side chain positions of Ala148 (yellow) and Met162
(orange) proteins are indicated, depicting the loss of the predicted hydrophobic interaction between residue 148 and Met162. The model of the
substrate binding pocket of the nsp5/S133N/V148A virus (E) and the nsp5/H134Y/V148A virus (F) are shown. Domain II backbone residues of
the nsp5/V148A virus are pale blue, and S133N (E) and H134Y (F) substitutions are yellow. In both panels, predicted amino acid positional
changes are dark blue.
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Met162 and the S1 subsite of the MHV nsp5 active-site
cavity. The CoV nsp5 protein is a highly conserved cysteine
proteinase that is essential for virus polyprotein processing and
replication. The 3C-like proteinase activity of nsp5 was first
experimentally confirmed in our laboratory (33) and, since the
SARS outbreak in 2003, has been a highly active area of re-
search and a major target for antiviral development (19, 21).
The results of this study provide new insights into the dynamic
structure-function relationships that occur during nsp5 pro-
cessing of replicase polyprotein substrates and identify novel
residues that may be critical for the proper function or regu-
lation of nsp5 activity. In particular, Met162 is known to be
part of the Tyr161-Met162-His163 (Y-M-H) motif that is con-
served in the substrate binding S1 subsite of the nsp5 active-
site cavity. Previously, Met162 was described as the “X” resi-
due of a “Y-X-H” S1 subsite motif analogous to the “G-X-H”
S1 site of other viral 3C and 3C-like proteinases, with the
His163 residue concluded to be critical for binding to the
P1-Gln residue of the substrate and the buried Tyr161 thought
to be critical for the stable tautomeric positioning of His163
(Fig. 5B) (1, 45). When WT MHV nsp5 was modeled, the
Val148 residue was found to be directly juxtaposed to the
Met162 residue. This same positioning of the Val residue prox-
imal to the Tyr161-Met162-His163 S1 subsite is reflected in the
crystal structures of transmissible gastroenteritis virus and
SARS-CoV (2, 3). Modeling of the Val148Ala mutation of
Alb/ts/nsp5/V148A predicts the loss of hydrophobic interac-
tions between residue 148 and Met162, allowing for greater
rotameric flexibility of the Met162 side chain. Overall, these
results suggest that the nsp5/Met162 MHV and its highly con-
served CoV nsp5 orthologs play an important role in the S1
subsite that was not previously predicted by structural studies.
The rapid emergence of Alb/ts/nsp5/V148A revertant vi-
ruses at 40°C demonstrates selection for a functional nsp5
molecule. Identification and confirmation of two independent
second-site revertant mutations (Ser133Asn and His134Tyr in
nsp5) indicate that the partial restoration of nsp5 function can
occur in more than one manner and that the adjacent Ser133
and His134 residues may play a role in the stability or function
of nsp5. Because Val148Ala is predicted to allow increased
rotameric flexibility of the Met162 side chain, which may de-
stabilize the active-site cavity of nsp5, it is reasonable to hy-
pothesize that the compensating mutations function to resta-
bilize the active-site cavity. The His134Tyr mutation is
predicted to subtly shift the positions of the His172 and Tyr182
residues that face Tyr161 and His163 (Fig. 5B). Orthologs of
His172 and Tyr182 proteins are highly conserved across differ-
ent CoV groups and are proposed to participate in forming the
base of the S1 subsite, which helps to maintain the stability of
His163 and interactions with the substrate. The Ser133Asn
substitution in nsp5 did not appear to modify any residues that
directly or indirectly interact with the active-site cavity or the
S1 subsite. In fact, the predicted changes are in amino acid side
chains that are directed away from the active site. One of these
affected residues, Arg131, is conserved across all CoV groups
and thus might affect nsp5’s function in an unknown fashion. It
is also conceivable that at higher temperatures, the Ser133Asn
substitution may propagate changes through His134 in a man-
ner analogous to that predicted for His134Tyr. Interestingly,
this revertant virus was less competent in virus growth at 30°C
and 40°C than either the WT or the nsp5/H134Y/V148 virus,
suggesting that Ser133Asn is a less-than-optimal “second-
choice” reversion. These possibilities remain to be tested by
genetic and biochemical studies.
Impact of nsp5/V148A on the design of small-molecule in-
hibitors of nsp5 for SARS-CoV. There is current research to
define and test inhibitors of SARS-CoV nsp5 3C-like protein-
ases (19–21). Recently, a cluster of serine residues (Ser139,
Ser144, and Ser147) was identified near the active-site pocket
of SARS-CoV nsp5 as being susceptible to targeting by com-
pounds containing boronic acid (3). Both Ser139 and Ser147
are conserved in the nsp5s of all CoVs, further defining this
region of nsp5 as an attractive target for drug development.
Interestingly, the Val148Ala mutation in nsp5 of Alb/ts/nsp5/
V148A is located adjacent to Ser147. Our results indicate that
CoV nsp5 proteins may possess an arsenal of adaptive mech-
anisms to respond to adverse conditions. The same type of
subtle modifications that allowed rapid reversion from a non-
functional ts nsp5/V148A mutant virus might provide the ca-
pacity for the virus to exclude protein, peptide, or chemical
substrate analog inhibitors of nsp5 proteinases while retaining
the capacity to process viral polyprotein substrates. It will be
critical and highly informative to test all proposed inhibitors
for resistant mutant viruses and to completely sequence the
nsp5 coding region and possibly the entire genomes of rever-
tant viruses that arise during tests of nsp5 inhibitors.
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